Pliant Therapeutics Inc (PLRX)
Healthcare
Biotechnology
1.00 $
-1.9%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Pliant Therapeutics Inc (PLRX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 91.4% of the shares are freely tradable; institutional investors hold 81.9%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
81.9%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
2.3%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
91.4%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
4.7%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
62Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 9.92 | 6,143,132 | +0.0 | 03/31/2026 |
| Citadel Advisors Llc | 5.21 | 3,226,599 | +24.9 | 03/31/2026 |
| Blue Owl Capital Holdings LP | 4.80 | 2,969,199 | +0.0 | 03/31/2026 |
| Vanguard Group Inc | 4.55 | 2,818,241 | +1.5 | 12/31/2025 |
| ADAR1 Capital Management LLC | 4.17 | 2,585,126 | +3,402.0 | 03/31/2026 |
| Acadian Asset Management LLC | 3.90 | 2,416,508 | +445,750.2 | 03/31/2026 |
| Vanguard Capital Management, LLC | 3.78 | 2,343,101 | +0.0 | 03/31/2026 |
| Two Sigma Investments LLC | 3.64 | 2,253,138 | +136.4 | 03/31/2026 |
| Monaco Asset Management | 3.13 | 1,938,747 | +0.0 | 03/31/2026 |
| Renaissance Technologies Corp | 2.99 | 1,852,842 | +77.2 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.